The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.

The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $55.00 expecting BLTE to rise to within 12 months (a possible 78.98% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a reiterated with a price target of $0.00 to $55.00. The current price Belite Bio (BLTE) is trading at is $30.73, which is within the analyst’s predicted range.